Topline data from the pivotal INFRONT-3 Phase 3 clinical trial of latozinemab in FTD-GRN expected by Q4 2025Anticipate completing enrollment in ...

Explore AC Immune's innovative Alzheimer's and Parkinson's therapies, key pharma collaborations, and financial outlook. Learn more on ACIU stock here.

With early diagnosis of Alzheimer's disease comes the possibility of treatment to not only help manage symptoms but also slow ...

Tau aggregates appear inside synapses from human brain samples with Aβ pathology. The method can be adapted to study other synaptic proteins. As reported in Cell Chemical Biology on January 23, first ...

Neurofibrillary tangles (NFTs) are a hallmark of Alzheimer’s disease, formed by the accumulation of tau protein into fibrillar structures. These tangles, composed of paired helical filaments and ...

The growth of the Alzheimer's Disease Therapeutics Market is directly influenced by the increasing prevalence of Alzheimer's disease globally. The hi ...

Tau is a protein that is found in cells of the central ... Biogen and Eisai have already filed for approval of their amyloid-targeting antibody aducanumab, and while some analysts see the evidence ...

Q4 2024 Earnings Call Transcript February 20, 2025 Prothena Corporation plc misses on earnings expectations. Reported EPS is ...

The mutation causes the brain to produce versions of the amyloid protein that are prone ... in 2023 — in combination with newer antibodies that attack tau.

Jaime Bortz, 39, is losing her memory to dementia. Her mom, now a full-time carer, is foreshadowing the burden many families ...